P. 1
Immune Susytem

Immune Susytem

|Views: 2|Likes:
Published by Karol Yap

More info:

Published by: Karol Yap on Jun 26, 2011
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as DOCX, PDF, TXT or read online from Scribd
See more
See less







BSN3-B Engineering Better Immune Cells

Scientists use synthetic biology to create drug-controlled T cells. Engineering a molecular control switch into immune cells could improve their therapeutic potential. Scientists from Caltech have shown that putting an RNA-based toggle mechanism into both live mice and human T cells allows them to turn cell growth on and off with a specific drug. The researchers ultimately hope to implement the technology in T cell therapeutics, which are currently in clinical testing for treating cancer and other diseases. "This system gives us the ability to control the fate and function of cell-based therapies," says Michael Jensen, director of the pediatric cancer program at the City of Hope, a research and treatment center in Duarte, CA, and an author of the paper. Scientists have long hoped to harness the power of the immune system to kill cancer cells, which can evade immune detection. One approach is to isolate T cells--a type of white blood cell that helps tailor the body's response to specific pathogens--from a patient's blood, multiply them, and then inject them back into the patient. Thanks to advances in genetic engineering and gene therapy, researchers are now modifying the isolated cells to better attack cancer. For example, a number of therapies now being tested in patients use T cells engineered to carry a molecule that allows them to selectively bind to cancer cells. These treatments have shown some success. One problem, however, is that unlike natural T cells, the engineered versions fail to multiply and don't persist in the bloodstream for long. That limits the cells' ability to recruit other parts of the immune system to kill the cancer. Giving patients an immune booster called interleukin 2 increases T cell survival and proliferation. However, the treatment is tough on patients--it requires chemotherapy and radiation to wipe out the natural T cells, enhancing the interaction between immune molecules and the modified cells. Christina Smolke, a bioengineer at Stanford University, and her collaborators are taking a different tack. In 2007, Smolke developed an RNA-based "on-off switch" using the principles of synthetic biology, an offshoot of genetic engineering in which scientists create functioning biological "parts" from molecular components. The device is designed to turn on expression of a certain gene in response to a chemical. In the new study, Smolke's team put the switch into T cells, creating a mechanism to control the cells.

technologyreview." Because the switch is made from RNA rather than proteins.com/biomedicine/25237/page2/ . Irvine points out that one concern in enhancing T cells' growth is the possibility that growth could spin out of control. coli. and engineering the switch into T cells with tumor recognition systems. Smolke's team is now working on altering the system to work with other FDA-approved drugs. demonstrating that the modified T cells only prospered when the animals were given the drug. "But they have an elegant solution. The switch was also effective in human cells. "It does address one of the problems with T cell therapies."We want to make them respond to inert molecules like vitamins. triggering production of an immune molecule that is crucial for T cell proliferation. which are inexpensive and easy to use and nontoxic for the patient.technologyreview. so that different drugs can be used to trigger production of other immune molecules." says Carl June. we get the same control over gene expression and downstream proliferation. The researchers injected T cells containing the construct into animals and then fed them theophylline." says Darrel Irvine. Scientists can swap in different sensor and actuator components. REFERENCES: http://www. and that it can slow tumor growth in animal models of cancer. they can turn it off. Smolke says clinical testing of the technology is still a ways off--they need to show that the system is safe in animals. "Through this drug. it may also avoid another issue with existing modified T cells--triggering an attack from the immune system. But the new study showed this particular part can work in human cells as well. and when we put the constructs into the cells. who was named one of TR's young innovators of the year in 2002." says Jensen. such as the research workhorses yeast and E.The toggle switch has an RNA sensor that responds to the asthma drug theophylline." says Smolke.com/biomedicine/25237/page1/ http://www. Another of the switch's benefits is its modular design. In addition to its implications for cancer treatment. a bioengineer at MIT who was not involved in the research. a pathologist at the University of Pennsylvania." he says. Most synthetic biology parts are created and tested in microbes. "An important feature of their system is that it should not trigger a T cell response against the cells themselves. which is survival and persistence of these cells. The new research was published this week in the Proceedings of the National Academy of Sciences. "We harvested T cells from humans. the research is a significant step forward for synthetic biology.

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->